Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
BPC-157 vs. Liraglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceVery limited comparison
At least one comparison profile is still being completed. Use the underlying compound records for the evidence currently available.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
BPC-157 is distinguished by most BPC-157 healing claims come from animal or laboratory experiments. Published human reports are small and uncontrolled, and the first sizable Phase 2 injury trial has not reported results; Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
BPC-157 is distinguished in the current record by most BPC-157 healing claims come from animal or laboratory experiments. Published human reports are small and uncontrolled, and the first sizable Phase 2 injury trial has not reported results. Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceLiraglutide
BPC-157: Profile in progress. Liraglutide: Mature human evidence.
Regulatory historyLiraglutide
BPC-157: Not approved. Liraglutide: FDA approved for defined product-specific indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
BPC-157
- Tendon and ligament injury models
- Muscle injury and return to sport
- Knee pain
- Ulcerative colitis
Liraglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Adolescent obesity
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
BPC-157Not approved
Not approved
LiraglutideFDA-labeled indications
FDA approved in product-specific daily injection formulations for chronic weight management, type 2 diabetes, and cardiovascular-risk reduction in a defined diabetes population.
Evidence depthEvidence, not a winner
BPC-157Profile in progress
A 53-person randomized ulcerative-colitis study is available only as a meeting abstract summarized by FDA; the published full papers are smaller uncontrolled reports.
LiraglutideMature Phase 3 + outcomes
Multiple randomized Phase 3 trials and the 9,340-participant LEADER cardiovascular outcomes trial, with adult and pediatric product-specific evidence.
Weight outcomesEvidence, not a winner
BPC-157Record incomplete
No dedicated weight-outcome summary has been editorially approved.
LiraglutidePeer-reviewed Phase 3
SCALE reported −8.4 kg mean change at 56 weeks versus −2.8 kg placebo. STEP 8 directly compared liraglutide 3.0 mg with semaglutide 2.4 mg.
Type 2 diabetesEvidence, not a winner
BPC-157Record incomplete
No dedicated diabetes-outcome summary has been editorially approved.
LiraglutideApproved + pediatric trial
Victoza has extensive adult evidence and controlled pediatric evidence beginning at age 10. Product-specific labeled doses differ from weight-management use.
Obstructive sleep apnoeaEvidence, not a winner
BPC-157Record incomplete
No dedicated obstructive-sleep-apnoea outcome summary has been editorially approved.
LiraglutideControlled study; not approved
A 359-participant trial found a larger reduction in apnea–hypopnea index than placebo, but no U.S. liraglutide OSA indication was identified.
Cardiovascular outcomesEvidence, not a winner
BPC-157Record incomplete
No dedicated cardiovascular-outcome summary has been editorially approved.
LiraglutideLEADER + labeled use
LEADER found fewer major cardiovascular events in adults with type 2 diabetes and high cardiovascular risk, supporting a defined Victoza indication.
Administration and handlingEvidence, not a winner
BPC-157Open profile
Open the compound profile for approved-label information or clearly identified trial-administration records.
LiraglutideDaily product-specific injection
Current approved products are once-daily subcutaneous, ready-to-use solutions. Saxenda and Victoza have different labeled dose ranges, purposes, and instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Very limited comparison
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Objective human efficacy, repeat-exposure safety, pharmacokinetics across promoted routes, and whether preclinical healing findings translate to people.
- Long-term comparative outcomes versus newer weekly incretin therapies and whether narrower research findings become approved uses.
Community Intelligence
Emerging patterns, clearly separated from evidence
BPC-157
No community experiences yetBe the first account holder to contribute.
Liraglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.